Biodesix 10-Q: Q3 Revenue $24.0M, Net Loss Narrows to $8.0M, Cash $28.4M
BDSX has more than doubled off its 52-week low of $5.26.
Summary
Biodesix's Q3 10-Q shows $24.0 million of revenue (up 10% but below the $27.5 million estimate), an $8.0 million net loss, and $28.4 million of cash after heavy ATM use; full-year guidance was cut to $101 million-$103 million.
Key Events · Earnings and Guidance · BDSX
-
Q3 Revenue Misses Consensus
Total revenue of $24.041 million rose 10% year over year but came in about 13% below the $27.5 million IBES estimate. Diagnostic Testing grew 16% to $23.055 million, while Development Services fell 49% to $0.986 million.
-
Full-Year Guidance Cut
The 2026 revenue outlook was revised to $101 million-$103 million, with the midpoint implying roughly 15% growth over 2025. The cut reflects Q3 results, sales team expansion timing and delayed Development Services contracts.
-
Loss Narrows, Cash at $28.4M
Net loss of $8.032 million improved 8% from $8.716 million a year ago. Cash and cash equivalents were $28.409 million at September 30, 2026, up from $18.987 million at year-end 2025.
-
Heavy ATM Use Drives Share Growth
Nine-month ATM sales totaled $30.4 million gross (2,460,441 shares at a $12.38 weighted average), lifting shares outstanding to 11.05 million from 8.25 million at December 31, 2025. At quarter-end, $12.2 million of ATM capacity remained.
Analysis · BDSX · Industrial Applications And Services
The 10-Q fills in the numbers behind today's 8-K and guidance cut. Revenue of $24.041 million rose 10% year over year but fell short of the $27.5 million consensus, and the full-year outlook was trimmed to $101 million-$103 million. The quarter's net loss narrowed to $8.032 million from $8.716 million, and cash stood at $28.409 million at quarter-end after $6.6 million of gross ATM proceeds in Q3. On the balance sheet, $50.0 million of Perceptive term debt carries a roughly 12.92% rate, with maturity pushed out to November 21, 2028. Dilution is already visible in the share count: 11.05 million shares outstanding versus 8.25 million at year-end 2025, reflecting $30.4 million of nine-month ATM sales and 228,691 shares issued on Perceptive's cashless warrant exercise.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDSX was trading at $16.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $209.3M. The 52-week trading range was $5.26 to $31.97. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.